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Lymphocyte activation leads  to the orderly expression of antigens  that  were 
absent or only weakly expressed on the surface membranes of the resting cells. 
The functions of some of these induced antigens on human cells are now known 
to include receptors for transferrin and insulin to enable rapid proliferation and 
increased expression of class  II  major histocompatibility complex molecules to 
augment interlymphocyte communication (1-3); the functions of other antigens 
defined by monoclonal antibodies (mAb) ~ such as 4F2 and T 10 await elucidation 
(2, 4). 
Relatively few activation antigens  are specific for T  cells, and it seems likely 
that such T  lineage-specific activation antigens (TLiSA) play an important role 
in  the  activation  or  regulation  of functional  T  cells.  Thus,  the  receptor  for 
interleukin  2  (IL-2-R),  detected  by mAb  such as anti-Tac (5-8),  although  not 
strictly  a  TLiSA  (9),  is  one  example  with  both  proliferative  and  regulatory 
functions (5-9), and  the T1 13 antigen,  which  is part  of the receptor for sheep 
erythrocytes, participates in the alternative pathway of T  cell activation (10). To 
date,  the  functions of the  TLiSA of tool wt  160,000  and  210,000,  which are 
subunits of the A-IA5  antibody-defined complex (11), and  the  Tal  of tool wt 
105,000 (12) are not known. 
In this report, we describe a  novel TLiSA that appears to be involved in the 
differentiation  of cytolytic  T  lymphocytes  (CTL),  and,  more  particularly,  of 
anomalous  killer  (AK)  cells  (13-16)  from  their  precursors.  LeoA1,  an  mAb 
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against this antigen,  inhibited the generation of these effector cells, but had no 
effect on proliferation or on effector cell function. The antigen named TLiSA1 
was clearly distinct from the  IL-2-R, although the kinetics of its expression on 
activated T  cells were similar to the appearance of this receptor and, like Tac, it 
was absent from a  number of leukemic T  cell lines. We consider the possibility 
that the antigen may function as a  receptor for a  human analogue of the T  cell 
differentiation factor that has been described in murine studies (17-19). 
Materials and Methods 
Preparation ofmAb.  BALB/c mice (maintained at The Walter and Eliza Hall Institute) 
were immunized over a period of 30 d by three intraperitoneai injections of l0  T human 
T  cells,  which  had  been  activated  by coculture with  irradiated  B  lymphoblasts,  and 
cultured in medium containing IL-2, and by a further intravenous boost 1 wk later. After 
3 d, spleen cells from the immunized mice were fused with NS-1  cells, and the hybrids 
selected with hypoxanthine, aminopterin, and thymidine (HAT), as described (20). The 
hybridoma supernatants were screened for selective binding to mixed lymphocyte culture 
(MLC)-activated T  cells by using indirect immunofluorescence and flow cytometry. Cells 
secreting an antibody of interest were cloned as described (20), and used to prepare ascites 
fluid in  BALB/c mice primed  with pristane.  A  radioimmunometric assay  was  used to 
isotype the antibodies, and LeoA1 and LeoA2 were determined to be IgGl~, and the 
LeoLFA-1 to be IgM~.  For direct immunofluorescent studies, the LeoA1 antibody was 
purified by DEAE chromatography and directly coupled to fluorescein isothiocyanate 
(FITC) by standard techniques. For immunoprecipitatxon and proliferation studies (see 
below), the purified antibody was coupled directly to cyanogen bromide-activated Seph- 
arose beads (Pharmacia Fine Chemical, Piscataway, N  J). F(ab')2 fragments of the antibody 
were prepared with pepsin at pH 3.5, as described (21). 
The anti-Tac antibody used in comparative biological studies was the generous gift of 
Dr. H. Waldman (National Institutes of Health, Bethesda, MD), and for immunoprecipi- 
tation studies, a comparable antibody against the IL-2-R (22) was the generous gift of Dr. 
E. Reinherz (Dana-Farber Cancer Institute, Boston, MA). 
Cell  Isolation.  Peripheral  blood  mononuclear cells  (MNC)  were  isolated  from  the 
heparinized blood  of normal  individuals  by  collecting cells  from  the  interface after 
centrifugation over lymphoprep (Nygard, Osio, Norway). The MNC  were washed and 
resuspended in RPMI  1640 medium containing 10% fetal calf serum (FCS), 5 ×  10  -5 M 
2-mercaptoethanol, penicillin (100 U/ml) and streptomycin (100 •g/ml)  (TC medium). 
Normal human thymocytes (from two donors) and bone marrow cells (three donors) were 
obtained from patients undergoing thoracic surgery. The thymocytes were monodispersed 
and separated from erythrocytes by mechanical disruption, passage through a wire sieve, 
and centrifugation over lymphoprep; bone marrow cells were washed with Eisen's balanced 
salt solution and centrifuged over lymphoprep. Interface cells were washed with Eisen's 
with 10% FCS, counted, and used for FACS analysis. 
Cell Lines.  Lines of normal human B lymphoblasts were established by infection with 
Epstein-Barr virus, as described (23).  The T  leukemic cell lines Molt 3 and Molt 4, and 
the fibroblast line Flow 2000 were obtained from Flow Laboratories Inc. (Melbourne, 
Australia), and the gibbon cell line MLA-144 (24) was a gift of Dr. Peter Hersey, Royal 
Newcastle Hospital, Newcastle, Australia.  Other cell lines including K562 (erythroleu- 
kemic), HL60 (promyelocytic), U937 (histiocytic), CEM (T cell leukemia), LiBr, and TAM 
(melanoma) have been maintained in the laboratory for a number of years, and are free 
of mycoplasma contamination (25).  Hybrid T  cell lines were made by preparing a HAT- 
sensitive variant of the CEM line, and then fusing this with MLC-activated T  cell blasts 
using polyethelene glycol. Hybrids were selected using HAT medium, and cloned by 
limiting dilution. 
Proliferation  Assays.  Proliferation assays were carried out in round-bottomed microti- 
ter  trays  (76-013-05  Linbro Chemical  Co.,  Hamden,  CT),  measuring  [SH]thymidine BURNS  ET  AL.  1065 
incorporation, as described (26). The effect of different dilutions of LeoA1 and control 
antibodies was tested on untreated MNC (for mitogenesis), and together with irradiated 
B lymphoblasts (for the effecf on MLC). MNC from at least three different donors were 
used  for each  assay, and  separate  plates  were  harvested  on days 2-8  to assess  kinetic 
effects.  The mitogenic assays were also carried  out  with  LeoA1 antibodies  coupled to 
Sepharose beads. 
Induction of CTL and AK Cells.  Autologous or allogeneic B lymphoblasts were irradi- 
ated (4,000 rad) and used to generate CTL and AK cells from MNC of normal subjects 
in  MLC, as given in detail  elsewhere  (15,  16,  20,  26).  Flasks containing the cells (Lux 
5375) were maintained upright for 7-10 d in 10% CO2 in air, and after this time the cells 
were harvested and counted for testing in cytotoxicity assays. These cultures induced both 
CTL and AK cells. The CTL were able to kill the stimulating B lymphoblasts and, at the 
effector phase, they could be inhibited from killing by monocional antibodies to T3 and 
T8 (15,  16, 20). The AK cells were tested by their ability to kill the LiBr melanoma cell 
line, a  cell which is insensitive to lysis by natural killer (NK) cells (16): the AK cells had 
not been sensitized against the melanoma cells and the killing could not be inhibited by 
antibodies to T3 or T8. 
Limiting-dilution  Assays.  CTL  and  AK  cells  were  induced  by  stimulating  limiting 
numbers of MNC with autologous or allogeneic irradiated B iymphoblasts (15). For this, 
graded numbers of responder MNC were added to each well ofa microtiter tray, together 
with 2  ×  104 irradiated autologous MNC (filler cells) and  104 irradiated B lymphoblasts 
(stimulator  cells).  The plates  were incubated  for 3  d, and  10%  (vol/vol) MLA-derived 
supernatant was added as a source of IL-2; thereafter,  the IL-2 was supplemented every 
3  d.  The cells  in each well  were assayed for cytolytic activity against the two different 
target cells: B lymphoblasts for CTL function, and LiBr for AK cell function. We added 
each of the ~Cr-labeled targets directly into the wells of half of each plate, and proceeded 
as described below for the cytolytic assay. In all experiments,  96 replicate cultures were 
set up at each responder cell concentration, and of these, 48 replicates were tested against 
each target cell.  Results for each well were considered positive when the release of ~Cr 
exceeded the mean of the 48 control wells (containing irradiated stimulator cells and filler 
cells only) by >3 SD. The fraction of negative cultures was plotted against the responder 
cell number;  the data were calculated according to the  zero-order term of the  Poisson 
probability distribution based on the least squares method, and the 95% confidence limits 
were  established  as  described  (15).  In  experiments  measuring  the  effect  of antibody 
LeoA1, the ultracentrifuged antibody was added as a final volume of 10% of hybridoma 
supernatant,  and  the parallel  series of (control) plates received  the same volume of an 
irrelevant mAb of the same isotype. 
51,  Cytotoxicity Assay.  We  used  Cr-release  assay,  as  described  (26).  Target  cells  were 
labeled with ~Cr (100 #Ci per  106 cells) and added to the wells of microtiter plates as 
5,000 cells/well.  Effector cells were added at different concentrations, the plates centri- 
fuged (400 g for 1 min), and incubated at 37°C for 4 h. The plates were then centrifuged 
again,  and  I00  •1  of supernatant,  containing  released  radioactivity,  was  removed  for 
measurement in the gamma counter. In bulk cultures,  the results were calculated as the 
mean percent specific lysis (msl) (26). The spontaneous release of 5~Cr by each of the cell 
lines used  was <10%, and the standard  deviation  of triplicate  mean  values was always 
<3% of the response. Significant differences between mean values were calculated by the 
one-tailed Student's t test. 
Cell Staining and Flow Cytometric Analysis.  Cultured  cells  were stained  by direct  or 
indirect  immunofluorescence  and  analyzed  using  a  fluorescence-activated  cell  sorter 
(FACS) (model  II, Becton  Dickinson  and  Co.,  Sunnyvale,  CA) as described  (27).  The 
FACS was also equipped with a  computer handling system, and three parameters  were 
measured for each cell: forward light scatter (related to cell size), fluorescence from FITC- 
conjugated antibodies,  and red fluorescence from propidium iodide, which was used to 
identify nonviable cells. In the antigen modulation studies, the antigens TLiSA 1 and Tac 
were removed from MLC-activated T cells, which had been cultured in IL-2, by incubating 
them overnight at 37 °C with LeoA 1 or anti-Tac, respectively. The modulated cells were 1066  FUNCTIONAL HUMAN  T  LINEAGE-SPECIFIC  ACTIVATION ANTIGEN 
then  stained  directly  with  FITC-labeled  LeoA1  or  rhodamine-labeled  anti-Tac,  and 
analyzed by dual-laser cytofluorimetry. 
Immunoprecipitation and Polyacrylamide Gel Electrophoresis (PAGE).  Human T cells that 
had been activated in MLC and cultured for 8 d  in medium containing IL-2, and cells 
from the MLA-144 gibbon cell line were surface labeled with ~25I by the Iodogen method 
(28) and immunoprecipitated with antibody, as described (26, 28).  The extracted lysates 
were precleared with uncoupled Sepharose beads and then Sepharose beads coupled to 
control (nonreactive) mouse mAb (kindly provided by Dr. A.  L6pez,  Walter and Eliza 
Hall  Institute)  before  precipitation  with  LeoA1  coupled  directly  to  Sepharose  beads. 
Sequential immunoprecipitations were performed in an identical manner, except that the 
lysates retained after the removal of TLiSA1  were used to precipitate IL-2-R with the 
anti-IL-2-R antibody coupled to Sepharose beads or, in  the reverse procedure,  LeoA1 
was  used to precipitate antigen  after the  removal of IL-2-R. The immunoprecipitates 
were washed, and run on 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide vertical slab 
gels (28). 
Competitive Binding Assay and Scatchard Analysis.  Purified LeoA 1 antibody was labeled 
with  125I to  10  #Ci/#g  protein  by the  chloramine-T  method,  and  saturation-binding 
experiments were performed with increasing numbers of activated T  cells.  The T  cells 
used were activated in MLC with irradiated B lymphoblasts for 6 d, then maintained in 
medium containing IL-2 for two additional days. For the competitive binding assays, 4 × 
105 cells were treated with decreasing amounts of ~25I-labeled LeoA1 in the presence or 
absence  of an  excess of unlabeled  LeoA1  for  1 h  at  4°C  (29).  A  binding  curve was 
constructed to ensure that saturation was obtained, and points on the linear portion of 
this curve were used to construct a curve of the Scatchard type, as described (29). On the 
ordinate was plotted r/A-x, which is equal to the bound counts divided by free counts, 
divided by the concentration of cells expressed in "moles per liter," which is equal to the 
number of cells per milliliter divided by 6.023 x  102o (29).  On the abscissa was plotted r, 
which  is  the  number  of antibody molecules bound  per  cell;  obtained  by dividing the 
number of antibody molecules bound per milliliter by the number of cells per milliliter. 
The regression line was fitted by the least squares method, with the aid of a computer. 
From this line, the x-intercept gives directly the maximum number of antibody binding 
sites per cell, which equals the number of antigens per cell if each antigen molecule binds 
only one antibody molecule. The slope from the line yields directly the reciprocal molar 
concentration of the association constant, Ka. 
Results 
Cellular Distribution of LeoA 1 Antibody Reactivity.  Peripheral blood cells from 
10 normal subjects were tested for reactivity with LeoA1 by indirect immunoflu- 
orescence and FACS analysis.  Granulocytes, erythrocytes, and platelets did not 
bind the antibody.  MNC  from eight subjects showed low or negligible binding 
with a  small proportion of cells that stained  with low fluorescent intensity (Fig. 
IA), and  the  resting cells from two individuals  had  10-20%  of cells displaying 
weak antibody  binding  (not  shown).  Monodispersed  thymocytes from  the  thy- 
muses  of two  children  were  analyzed  in  the  same  way,  and  these  showed  no 
antibody binding. Bone marrow cells from three adults did not bind LeoAl: this 
result was confirmed as zero binding by expanding the  5% of cells forming the 
tail of the fluorescence profile (which was identical to the control profile obtained 
using a  nonreactive mouse mAb) by use of the computer facility on the  FACS, 
and demonstrating that  this population  of cells had a  similar size and  90°  light 
scatter profile to the  original sample; morphological examination of these cells 
showed no enrichment of any particular cell type. 
LeoA 1 did not bind to any of the human cell lines tested. These included the BURNS  ET  AL.  1067 
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FIGURE  1.  Immunofluorescence profiles of human  MNC  before (left; A,  C, E)  and after 
(right; B, D, F) activation for  l0 d  in MLC. The cells were incubated with LeoA1  (A and B), 
LeoA2 (C and D), or LeoLFA-1  (E and F), and then FITC-labeled goat F(ab')2 anti-mouse 
F(ab')~. The dotted lines show staining in the absence of the first layer mouse mAb. 
leukemic T  cell lines CEM, Molt 3, and Molt 4; three B lymphoblastoid cell lines, 
K562, U937, and HL60; a fibroblastoid line; and two melanoma cell lines. Cells 
from the gibbon cell line MLA-144 displayed moderate antibody binding, and it 
is of interest that,  alone of the cell lines tested, the MLA-144 cells secrete IL-2 
and are dependent on this growth factor. Murine CTLL cells (an IL-2-dependent 
cell line) did not bind LeoA1. 
After MLC of MNC with irradiated  B lymphoblasts, the resultant T  iympho- 
blasts  expressed  strong  binding  with  LeoA1  (Fig.  1B).  This  was  not  due  to 
expansion of a small subpopulation of LeoA 1  + cells, since pretreatment of MNC 
with  LeoA1  and complement had  no effect on proliferation  or on subsequent 
antigen expression (data not shown). For comparison,  Fig.  1, C and D show the 
binding of an activation-specific antibody, LeoA2, which is not lineage-specific 
but is closely associated with proliferation, and Fig.  1, E and F show the binding 
of an  antibody,  LeoLFA-I,  with  the  same  specificity  and  function  as  other 
antibodies to LFA-1  (T.  Triglia,  unpublished observations).  Results with these 
control antibodies suggest that the binding of LeoA 1 is not absolutely dependent 
on cell proliferation, and show that the increased antibody binding after activa- 
tion is not the result of a  nonspecific increase in surface antigen expression.  In 
MLC  experiments  with  the  MNC  from  eight  different  normal  subjects,  the 
distribution  of binding  of LeoA1  to  the activated  T  cells was  Gaussian  on  a 
logarithmic scale (Fig.  1 B), and strong binding of LeoA1 by these activated cells 
was observed over 4 wk of culture.  Moreover, after cloning and maintenance of 
the T  cells in IL-2-containing medium for 2-3 m, these cells continued to bind 
LeoA 1. 
Kinetics  of Expression  of LeoA1  Reactivity  on  Activated  T  Cells.  MNC  were 
stimulated with the lectin phytohemagglutinin (PHA), and monitored for binding 
of LeoA 1 at various time points. One of three such experiments is illustrated in 
Fig.  2.  An  increase  in  antibody binding  was seen by 24 h  of culture,  but the 
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FIGURE 2.  Kinetics of the expression of binding of LeoA1 antibody to human  MNC after 
stimulation with PHA. Cells were stimulated with PHA (0.5 ~g/ml), then tested for binding 
of LeoAl antibody by indirect immunofluorescence at each of the time points indicated in the 
top right corner of each panel. The main panels illustrate the immunofluorescence profiles, 
dotted lines show fluorescence in the absence of LeoA1; each inset displays the fluorescence 
intensity (ordinate) versus the relative cell size (abscissa).  Nonviable cells have been gated out. 
the  number  of cells  binding  LeoA1  continued  to  increase  through  96  h  of 
culture. It is also clear from Fig. 2 (inset) that it is not only the large (presumably 
dividing) cells that bind LeoA 1. These data indicate that the antigen bound by 
LeoA 1 is an "early" activation antigen (1), although the kinetics of its expression 
and the persistence of expression appear to be slower and longer than  that of 
the IL-2-R on PHA-activated T  cells. 
Characterization  of the TLiSAI Antigen  Recognized by LeoA1.  Surface labeling 
of alloantigen-activated  T  cells  with  125I,  and  immunoprecipitation  and  gel 
analysis of the extract (Fig.  3) showed that  the  LeoA1  antibody precipitated  a 
single  broad band  spread  over an  area representing  a  range  of Mr -65,000- 
75,000.  When surface-labeled MLA-144 cells were used, a  much sharper band 
of Mr 95,000  was obtained  (Fig.  3).  The  reasons for this  discrepancy are  not BURNS ET  AL.  1069 
FIGURE 3.  Immunoprecipitate of the TLiSA1 antigen from human T cell blasts and from 
cells of the gibbon MLA-144 cell line. Cells were surface-labelled with ~2sI by the Iodogen 
method, immunoprecipitated with LeoA1, and run out on 7.5% SDS-PAGE  under reducing 
conditions. The first track shows the preclear of human T blasts with Sepharose beads coupled 
to an irrelevant mouse mAb. The second shows the same lysate precipitated with Sepharose- 
LeoA  1, and the third shows the absence of immunoprecipitate when labeled K562 cells were 
treated with Sepharose-LeoA  1. The dark spots at -220,000 tool wt in 2 and 3 are nonspecific 
spots on the autoradiograph. The right panel shows the precipitate obtained when MLA-144 
cells were immunoprecipitated with LeoA  1 under the same conditions. The molecular weight 
markers are:  ferritin  subunit (220,000), phosphorylase b (94,000), albumin (67,000), and 
carbonic anhydrase (30,000). 
clear,  but  immunoprecipitation  obtained  from  the  activated  T  cells  of some 
subjects  revealed a  weak  band  in  the  region  of Mr  95,000,  in  addition  to  the 
strong band at Mr 70,000. 
Cell Surface Expression of TLiSA1 Antigen.  Cold antibody displacement of 12~I- 
labeled LeoA 1 was used to determine the number of antibody-binding sites per 
MLC-activated T  cell blast; two independent experiments gave the same result. 
Analysis  of the  results  (Fig.  4)  showed  that  LeoA1  bound  to  a  maximum  of 
66,000 sites per cell, with an association constant, Ka, of-  1.1  X  109/M. 
Function  of the LeoA1 Antibody.  The LeoA1 antibody was tested for its mito- 
genic effect on the MNC of six donors at different times.  The antibody had no 
direct mitogenic effect at final  dilutions of 1:100-1:5,000 of ascites,  nor when 
coupled to  Sepharose  beads,  when  the  cells  were  assayed for proliferation  on 
days 3,  4,  5,  and  6  (data  not shown).  The antibody also had  no effect on the 
proliferation  induced  either  with  PHA  (data  not  shown)  or  with  irradiated 
ailogeneic B  lymphoblasts (Table  I).  Because of the  effect of LeoA1  on  MLC- 
induced maturation of CTL and AK cells (see below) it was particularly important 
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FIGURE 4.  ~251-1abeled  LeoA1 binding to human T  cell blasts. The binding of nanograms of 
added antibody to saturating amounts is shown; the inset shows Scatchard analysis of the data. 
From this experiment, the maximum number of antibodies bound was 66,000 per cell, with a 
Ka of 1.1  x  109/M. 
TABLE  I 
Effect of LeoA1 and Anti-Tac Antibodies  on the Proliferation of MNC 
Induced with Allogeneic B Lymphoblasts 
Proliferation 
Antibody  (cpm +SD) 
Control (25  E11)  56,280 -  3,186 
LeoA1  56,410 _  4,942 
Anti-Tac  18,808 _+ 3,049" 
The proliferation shown is that obtained with MNC after 6 d of culture 
in the presence of antibody at a final dilution of 1:5,000 ascites. 
* P <0.001  by Student's t test. 
the proliferative  response.  The experiment  shown in Table I  was repeated on 
MNC from six different subjects, with antibody present at final dilutions between 
1:100 and 1:5,000, and with harvesting of the plates at days 4-8 of the response. 
On no occasion did the proliferation in the presence of LeoA 1 differ significantly 
from that  in the presence of an antibody of irrelevant  specificity, whereas the 
anti-Tac  antibody  significantly  inhibited  proliferation  even  when  present  at  a 
final dilution of 1:5,000 ascites (Table I). 
The ability of LeoA 1 to block the effector phase of killing of B lymphoblasts 
by CTL,  and  of melanoma  cells by AK cells generated  in  the  same  MLC was 
tested by adding antibody to the cultured effector cells immediately before, or 
30  min  before,  the  addition  to  ~lCr-labeled  target  cells,  and  then  measuring 
cytotoxic activity. A control antibody that does not bind to T  cells (25 E11) was 
included in every experiment, and the LeoLFA-1 antibody, which inhibits killing 
by CTL, AK, and natural killer cells (T. Triglia, unpublished data) was included 
as a  positive control.  LeoA1  failed to inhibit  killing  mediated by CTL or AK 
cells (Table II), with similar data being obtained in seven separate experiments. 
In marked contrast, the addition of LeoA 1 to MLC at the beginning of culture BURNS  ET  AL.  1071 
TABLE  II 
Antibody LeoA1  Does Not Inhibit Killing by CTL or AK Cells at the Effector Phase 
Exp.  Antibody  Final antibody 
dilution* 
Cytolysis against* 
B lymphoblasts  Melanoma cells 
% 
Control (25 El 1)  1:800  58 +  2.5  61 +  3.7 
LeoA1  1:800  58 +  1.8  67 +  2.4 
LeoLFA-1  1:800  19 +  3.20  37 -  2.7~ 
Control (25 E11)  1:30  12 +  0.6  31 +  2.4 
1:300  13 +  0.4  30 +  0.9 
LeoA1  1:30  13 +  0.5  29 +  2.4 
1:300  12 +  0.6  29 +  1.7 
LeoLFA-1  1:30  7 +  0.4  g  17 +  0.90 
1:300  4 +  0.1 a  10 +  0.50 
* The dilution given is the final dilution of ascitic fluid in each well.  In each assay the ascitic fluid 
was diluted and ultracentrifuged before testing for blocking activity. 
CTL  and  AK  cells  were  generated  by  coculture  of MNC  with  irradiated  B  lymphoblasts, as 
described in Materials and Methods. After culture, the activated T  cells were harvested and tested 
against the stimulating B  lymphoblast and melanoma cells. The lysis shown is the percent mean 
specific lysis +SD from three replicates at an effector/target ratio of 10:1 from cells harvested after 
6 d of culture. 
JP <  0.001 by Student's t test. 
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TABLE  III 
Inhibition  of the Generation  of CTL and AK Cells by the Presence of LeoA1 or Anti-Tac 
During MLC 
Exp.  Antibody  Isotype or fragment 
Cell lysis 
B lymphoblasts  Melanoma 
LU* 
WEM-G 11  IgG 1  420  900 
LeoA 1  IgG 1  170  430 
25 E11  |gG2a  450  920 
Anti-Tac  lgG2a  430  910 
WEM-G11  IgG1  308  615 
WEM-G11  F(ab')2  308  615 
LeoA 1  IgG 1  83  66 
LeoA 1  F(ab')~  80  114 
Anti-Tac  IgG2a  25  229 
* Cell lysis data are expressed as the lytic units (LU) per l0  T ceils causing 30% lysis, obtained from 
the effector cells grown in flasks for 6 d with antibodies present at a final concentration of 1:2,000 
ascites in  exp.  1.  The  F(ab')~ results shown in exp.  2  were obtained at a  concentration of 150 
tag/ml; a  range of concentrations was tested, with similar results. The cells were then harvested, 
counted, and tested for cytotoxicity against B  lymphoblasts and melanoma cells over a  range of 
effector/target ratios. 
resulted  in  a  great  reduction  in  the  activity  of  induced  effector  CTL  and  AK 
cells  (Table  III).  The  antiproliferative  effect  of anti-Tac  was  excluded  in  these 
experiments,  since  they  were  carried  out  by  setting  up  the  MLC  in  flasks  and 
then  testing  the CTL  and  AK  effector  cells over  a  range  of effector/target  ratios. 1072  FUNCTIONAL  HUMAN T  LINEAGE-SPECIFIC  ACTIVATION  ANTIGEN 
The results (Table III) indicated that  LeoA1  inhibited the generation of both 
CTL and  AK effector cells,  and  that anti-Tac did  not consistently inhibit this 
process. Since it is known that the Fc fragment of antibodies can exhibit inhibitory 
effects (30),  the experiments were repeated with  F(ab')2  fragments of LeoA1. 
The F(ab')2 fragments consistently inhibited the development of CTL and AK 
effector cells at a  final concentration as low as 30 ttg/ml (Table III).  Also, the 
addition of LeoA 1 after  1 d  of coculture resulted in the same inhibitory effect 
(Table  IV),  indicating  that  the  antibody  was  not  interfering  with  a  primary 
recognition  event.  The addition  of antibody on days 4  (data  not shown) or 6 
(Table  IV)  did  not  lead  to  any  inhibitory  effect.  The  experiments  shown  in 
Tables III and IV were repeated six times using MNC from different subjects, 
all with similar results.  We then decided to determine the effect of LeoA1  on 
the  frequency of CTL  and  AK  cells  generated  under  conditions  of limiting 
dilution. 
In  two experiments,  the presence of LeoA1  from the  beginning  of culture 
decreased the numbers of CTL developing from their precursors from 1:450 (in 
the presence of control antibody) to  1:750 (Fig.  5), and from  1:900 to  1:1,750 
(not shown); the frequency of AK cells generated in the same experiments was 
also greatly reduced, from 1:200 to 1:1,550 (Fig. 5), and from 1:400 to 1:1,800 
(not shown). The proliferation obtained in these cultures could not be measured 
directly, but microscopic examination of the wells before testing for cytotoxicity 
confirmed our previous results that LeoA1 did not inhibit proliferation. Never- 
theless, when we analyzed these data as the mean cytotoxicity obtained for all of 
the wells at each different concentration of responder cells added, we found that 
the presence of LeoA1  reduced significantly the levels of cytotoxicity obtained 
at every responder cell concentration, even when all of the wells were positive 
and  therefore  excluded  from  Poisson  analysis  of  the  limiting-dilution  data. 
Together, these findings suggest that LeoA 1 antibody inhibited the development 
of CTL and AK cells without affecting the proliferation of their precursors. 
Discrimination  of the  TLiSA1  and  Tac  Antigens.  As  shown  in  Table  I,  the 
LeoA 1 antibody, unlike anti-Tac, did not inhibit the proliferation of activated T 
TABLE  IV 
Inhibition of the Generation of CTL and AK Cells by the Addition of LeoAl 
During MLC 
Day anti-  Cytolysis  against* 
Antibody*  body added  B lymphoblasts  Melanoma  cells 
% 
Control (25 Ell)  0  31 + 1.8  61 + 2.1 
LeoA1  13 + 0.46  38 __+ 1.6~ 
Control  1  31 + 3.9  57 +  1.8 
LeoA1  11 + 0.7  !  30 +- 3.8  ~ 
Control  6  30 + 1.1  55 _  1.6 
LeoA1  30 + 3.0  56 + 5.1 
* Antibody was added to a final dilution of 
* As in Table II. 
J P <0.001 by Student's t test. 
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FIGURE 5.  Limiting-dilution analysis of cytotoxic precursor cells from blood MNC generated 
in MLC with irradiated B lymphoblasts in the absence (  ) and presence (- -  -) of LeoA1 
antibody. Control antibody or LeoA1 was added on day 0, and a source of IL-2 was added on 
days 3, 6, and 9. The cultures were tested on day 10 for cytotoxicity against the stimulating B 
lymphoblasts for CTL (left),  and against unrelated melanoma cells for AK cells (right).  Each 
data point was determined from 48 cultures, and the lines were fitted by the method of least 
squares. Error bars are the 95% confidence limits obtained from Geigy's statistical tables. 
cells. This does not exclude, however, the possibility that the two antibodies are 
detecting different  epitopes on  the  same antigen,  with  only anti-Tac  blocking 
the actual binding site for IL-2.  That  LeoA1  was not detecting an epitope on 
the IL-2-R was shown in four ways: (a) LeoA1 was used to strip PHA-induced T 
cell blasts of all detectable TLiSA1, and the cells were used to absorb IL-2 from 
the  supernatant  of MLA-144 cells.  After this  treatment  it was found that  the 
TLiSA 1- cells absorbed IL-2 equally as well as untreated control blasts (data not 
shown).  (b)  In  fluorescent  antibody  binding  studies,  removal  of TLiSA1  by 
modulation with  LeoA1  overnight  at  37°C did not affect the level of staining 
with  the  anti-Tac  antibody,  and  modulation  in  the  reverse  direction,  by first 
removing  Tac,  did  not alter  the  expression  of TLiSA1.  (c)  The  same results 
were obtained in sequential immunoprecipitation  experiments using the iysates 
of T  cell blasts surface labelled with ~25I. Preclearing the lysates with anti-IL-2- 
R  did not reduce  the  TLiSA1  precipitate  obtained  with  LeoA1  precipitation, 
and conversely, removal of TLiSA 1 did not reduce the subsequent amount of 
IL-2-R precipitated by the anti-IL-2-R antibody (data not shown). (d) A  cloned 
hybrid cell line was constructed between MLC-activated T  cell blasts and a HAT- 
sensitive variant  of the  CEM  cell  line.  This  hybrid line  expresses T3  and  T4 
antigens  but  does  not  respond  to  nor  produce  IL-2  (data  not  shown).  Using 
indirect immunofluorescence and FACS analysis, we found that this clone (and 
several others from different fusions) expressed the TLiSA1  but not Tac (Fig. 
6). 
Discussion 
Activation antigens that are lineage specific appear to be likely candidates in 
the search for important functional molecules. In this paper, we study an antigen, 
TLiSA1, which was absent from the surface of a  variety of normal tissue cells, 
transformed  cells, and  tumor cell  lines,  but which  was expressed on activated 
human T  cells and short-term cultures of these ceils, and on a retrovirus-infected 1074  FUNCTIONAL  HUMAN  T  LINEAGE-SPECIFIC  ACTIVATION  ANTIGEN 
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FIGURE 6.  Immunofluorescence profiles of various cell lines indicated, treated with LeoA1 
or anti-Tac antibody, then FITC-labeled goat F(ab')~ anti-mouse F(ab')~. The dotted  lines 
show  staining in  the  absence of the  first  layer  mouse  mAb.  (A) peripheral  blood  T  cells 
activated in MLC; (B) a hybrid cell line (47C7) between MLC-activated T  cells and CEM cells; 
(C) the CEM cell line; (D) the gibbon cell line MLA-144. 
primate  T  cell  line.  This  distribution  pattern  distinguishes  the  antigen  from 
several other known activation antigens  that are not lineage specific (1-3,  31), 
and places it alongside the very few T  lineage-specific activation antigens  that 
have been reported  (5,  10-12).  Size alone  is sufficient to distinguish  TLiSA1 
from the  160 and 210 kilodalton (kD) subunits of the A-1A5-defined complex 
of Peters et ai. (11) and from both the T11~ (10) and Tal (12) antigens described 
previously. 
TLiSA1, however, appeared as a broad band after SDS-PAGE, a feature that 
is also characteristic of Tac (32). Although the Tac antigen is usually described 
as being of Mr 52,000-57,000  on normal activated T  cell blasts (32), estimates 
of its size vary, and it has been described (9,  12) as a band of 60-65 kD.  Also, 
the numbers of molecules of anti-Tac and LeoA 1 antibodies bound by activated 
lymphoblasts are approximately equivalent (32), as is the kinetics of expression 
of both  antigens  after  PHA  stimulation  of resting  MNC.  It  was  important, 
therefore, to distinguish TLiSA1 from Tac. Removal of TLiSA1 from the surface 
of T  blasts did not prevent these cells from absorbing IL-2, and the two antigens 
did not comodulate or coprecipitate,  indicating  that they are not linked.  Anti- 
Tac antibody did not bind to the MLA-144 gibbon cell line, which was TLiSA1 +, 
but this is most likely due to absence of the Tac epitope on primate cells, since 
this line is IL-2-dependent.  More pertinent was the existence of a human T  X T 
hybrid cell line that was TLiSA1 +, Tac-. This line expressed other T cell antigens 
and  activation  antigens  (T.  Triglia,  unpublished  observations),  and  would be 
expected to express the Tac epitope if the gene was expressed (11). Thus,  the 
results  strongly  support  the  independence  of TLiSA1  and  Tac,  and  perhaps BURNS ET AL.  1075 
suggest that  the  genes coding  for these two proteins are on separate  chromo- 
somes. 
In experiments  using  MLC to generate  CTL and  AK cells,  the presence  of 
LeoA1  antibody inhibited  the  induction  of mature  effector cells,  but did not 
affect proliferation.  It is now being recognized that the appearance of AK cells 
in  both mouse and  man  is caused by activated T  cells that are able to kill  NK 
cell-resistant target cells (13-16,  33-36), and not by residual NK cells. Indeed, 
the  current  concept  of AK  cells  is  that  they  arise  in  culture  by the  further 
differentiation of MHC-restricted CTL (16, 33, 37-40).  If this is so, the results 
described herein suggest that LeoA1 antibody is inhibiting the differentiation of 
the precursors of CTL, and of CTL cells themselves. 
The  mechanism  of this  inhibition  is  speculative.  Suppressor  cells  may  be 
activated by the antibody but, since suppressor mechanisms probably operate by 
preventing proliferation (41), this seems unlikely. It has been suggested (42) that, 
in mice, differentiation of T  cells can be dissociated from proliferation, and that 
a differentiation molecule distinct from I L-2 is involved in this process (17-19, 
43).  It is possible, therefore,  that  LeoA1  acts by interfering  with human  cells' 
uptake of a  homologous factor,  or by interfering  with  the  function  of such a 
factor. Investigation  of this possibility is the subject of current research in our 
laboratory. 
Summary 
The  characteristics  of a  novel T  lineage-specific  activation  antigen,  termed 
TLiSA1,  are  described.  The  antigen  was  detected  with  a  mouse  monoclonal 
antibody, LeoA 1,  that was raised against activated human  T  cells generated  in 
mixed lymphocyte culture (MLC). The antigen became strongly expressed on T 
cells 48-72 h after stimulation with phytohemagglutinin, and retained expression 
on MLC-activated T  cells after  10 d  of culture. The antigen was absent from a 
range of human T, B, myeloid, fibroblast, and tumour cell lines, but was present 
on the surface of the interleukin  2 (IL-2)-dependent gibbon cell line MLA-144. 
Analysis of the antigen  by sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis of immunoprecipitates obtained from activated human T  cells demon- 
strated a broad hand in the region of 70 kD, whereas precipitates obtained from 
MLA-144 revealed a single narrow band of 95 kD. The molecule was expressed 
with  a  maximum  density  of 66,000  copies per  cell  on  the  surface  of MLC- 
activated  T  cell  blasts,  as  assessed  by Scatchard  analysis.  TLiSA1  was  distin- 
guished from the IL-2 receptor bound by the anti-Tac monoclonal antibody by 
demonstrating  that  the  antigens  did  not  comodulate or  coprecipitate,  and  by 
constructing  an  IL-2-independent  human  T  ×  T  hybrid  that  expressed  the 
TLiSA1 but not the Tac antigen. MLC with B lymphoblasts was used to generate 
cytotoxic T  lympbocytes (CTL) specific for the stimulating cell, and anomalous 
killer (AK) cells able to kill ~nelanoma  target cells. The presence of LeoA1  or 
F(ab')2 fragments of the antibody from the beginning of coculture did not affect 
proliferation  in  these cultures,  but did inhibit  the induction  of both CTL and 
AK cells from their precursors. This inhibition of differentiation by LeoA1 was 
confirmed  under  conditions  of limiting  dilution,  where it  was shown that  the 
antibody reduced  the  frequency of CTL  produced,  and  greatly  (fourfold) re- 1076  FUNCTIONAL HUMAN  T  LINEAGE-SPECIFIC  ACTIVATION ANTIGEN 
duced  the  frequency of AK cells  generated  from their  precursors.  We discuss 
the  possibility  that  human  CTL  may express a  differentiation  factor  receptor 
that is distinct from the receptor for IL-2. 
We thank Drs. I. R. MacKay and J. F. A. P.  Miller for critical review of the manuscript, 
and Filomena Lauriola for excellent technical assistance. 
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